MBX Biosciences, Inc.

Contributing Author

Recent Articles by MBX Biosciences, Inc.

1 hour	MBX Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) MBX GlobeNewswire
Mar-12	MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights MBX GlobeNewswire
Mar-10	MBX Biosciences Appoints Karen Basbaum as Chief Business Officer MBX GlobeNewswire
Mar-09	CORRECTING & REPLACING -- MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism MBX -8.54% GlobeNewswire
Mar-09	MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism MBX -8.54% GlobeNewswire
Feb-23	MBX Biosciences to Participate in Upcoming March Investor Conferences MBX +5.63% GlobeNewswire
Feb-11	MBX Biosciences to Participate in Upcoming Investor Conferences MBX -7.11% GlobeNewswire
Jan-22	MBX Biosciences Appoints Laurie Stelzer to Board of Directors as Audit Committee Chair MBX GlobeNewswire
Jan-11	MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference MBX GlobeNewswire
Dec-15	MBX Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13 MBX GlobeNewswire
Nov-18	MBX Biosciences to Participate in the 37th Annual Piper Sandler Healthcare Conference MBX GlobeNewswire
Nov-06	MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights MBX +9.71% GlobeNewswire
Oct-20	MBX Biosciences to Participate in November Investor Conferences MBX +7.64% GlobeNewswire
Sep-29	MBX Biosciences to Participate in the Stifel 2025 Virtual Cardiometabolic Forum MBX GlobeNewswire
Sep-24	MBX Biosciences Announces Pricing of Upsized Public Offering MBX -13.78% GlobeNewswire
Sep-22	MBX Biosciences Announces Proposed Public Offering MBX +100.00% MBX -5.20% GlobeNewswire
Sep-22	MBX Biosciences Announces Once-Weekly Canvuparatide Achieved Primary Endpoint in Phase 2 Trial with 63% Responder Rate at 12 Weeks; 79% Responder Rate at 6 Months in Open-Label Extension MBX +100.00% GlobeNewswire
Sep-19	MBX Biosciences to Provide Topline Results from its Phase 2 Trial of Potential Once-Weekly Canvuparatide for Hypoparathyroidism (HP) on Monday, September 22 MBX GlobeNewswire
Sep-04	MBX Biosciences Doses First Participant in Phase 1 Trial of MBX 4291 for the Treatment of Obesity MBX -10.28% GlobeNewswire
Aug-07	MBX Biosciences Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights MBX GlobeNewswire
Jun-23	MBX Biosciences Appoints Andreas Moraitis, M.D., as Senior Vice President of Clinical Development MBX GlobeNewswire
Jun-16	MBX Biosciences Announces IND Submission of MBX 4291, its Long-acting GLP1/GIP Receptor Co-agonist Prodrug for the Treatment of Obesity MBX GlobeNewswire
Jun-10	MBX Biosciences to Present at the American Diabetes Association 85th Scientific Sessions MBX GlobeNewswire
May-20	MBX Biosciences to Participate in June Investor Conferences MBX GlobeNewswire
May-12	MBX Biosciences Reports First Quarter 2025 Financial Results and Recent Corporate Highlights MBX GlobeNewswire

MBX Biosciences, Inc.

Recent Articles by MBX Biosciences, Inc.

Upgrade your Finviz experience